|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||79.30 - 82.80|
|52 Week Range||60.81 - 113.06|
|PE Ratio (TTM)||N/A|
|YTD Daily Total Return||-8.77%|
|Beta (5Y Monthly)||1.80|
|Expense Ratio (net)||0.95%|
Read a comparison of BIB and LABU and a description of the characteristics and historical performance of these leveraged biotech ETFs.
Marc Lichtenfeld, an expert in biotech and income stocks, notes that a lot of Wall Street money moves into companies that issue positive Phase 2 clinical trial data.